Tissue Regenix provided revenues guidance for the year 2019. The company has revealed that its 2019 revenues will be below current market consensus, although it stressed that demand for its products remains strong. The increase in throughput is now expected to become available during the fourth quarter of 2019 and, as such, the board anticipates that revenue for 2019 will be below current market consensus by approximately 15% to 20%, with a corresponding reduction in margin impacting EBITDA (earnings before interest, taxation depreciation and amortisation).